CTRVPOTC

Hepion Pharmaceuticals, Inc.

Healthcare·Oncology·Phase 3·Morristown, NJ, United States
OncologyImmunologyCardiovascularInfectious DiseaseMetabolicNephrologyGastroenterology

Hepion Pharmaceuticals, Inc. (CTRVP): 4 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.

6.6/10

BioSniper Score

6-factor signal · derived from public data

Cash Runway2.8

9.9 months

Financial Health9.3

D/E 0.46 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst Momentum2.0

1 upcoming, next in ~474d

Insider Signal10.0

5 buys · 0 sells (180d)

A transparent, data-derived signal for Hepion Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$15K

Cash

$2.6M

Quarterly Burn

$799K

Runway

9.9 mo

Revenue

—

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Apr 2027
Today~17 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (4 candidates)

DrugPhase
alxn2220Phase 3
ravulizumabPhase 3
Rencofilstat (formerly CRV431; CPI-431-32)Phase 2
rencofilstat (formerly CRV431)Phase 2

Upcoming Catalysts (1)

Phase3_ToplinePhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

3 clinical trials·CEO: Mr. Gary S. Stetz CPA

Frequently asked questions

How many drug candidates are in Hepion Pharmaceuticals, Inc.'s pipeline?

Hepion Pharmaceuticals, Inc. (CTRVP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Hepion Pharmaceuticals, Inc.'s lead drug candidate?

Hepion Pharmaceuticals, Inc.'s most advanced tracked candidate is alxn2220 (Phase 3) for Transthyretin Amyloid Cardiomyopathy.

What is Hepion Pharmaceuticals, Inc.'s next catalyst?

Hepion Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy " — expected October 5, 2027.

What is Hepion Pharmaceuticals, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Hepion Pharmaceuticals, Inc. has approximately 9.9 months of cash runway.

What is Hepion Pharmaceuticals, Inc.'s market capitalization?

Hepion Pharmaceuticals, Inc.'s market capitalization is approximately $15K.

Get the full picture on Hepion Pharmaceuticals, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar